Grants>Disease-Specific Research

2013 Request for Proposals for Grants Related to Pediatric Mast Cell Disorders (Pediatric Mastocytosis and Pediatric Mast Cell Activation Syndrome)

The Mastocytosis Society, Inc. (TMS) and Mastokids (MKO) are pleased to announce that we are accepting proposals for research grants for new or ongoing projects related to Pediatric Mastocytosis or Pediatric Mast Cell Activation Syndrome.

An amount of $60,000 is available for this grant.

Submission deadline: Proposals must be received by June 1, 2013

Lustgarten Foundation Research Funding Opportunities

Concept Due Date:  May 24, 2013

Full Applications Due: August 9, 2013

Funding to begin January 2014

The Lustgarten Foundation (LF) is the nation’s largest private funder of pancreatic cancer research. Our mission is to advance scientific and medical research related to the diagnosis, treatment, cure and prevention of pancreatic cancer. Thanks to the support of Cablevision, 100% of all our donations go directly to research, which has enabled us to commit $65 Million to outstanding research projects to date.

For the 2013 Grant application cycle, The Foundation’s Scientific Review Board has identified a number of research areas for which proposals are now being solicited (below).

Research Topics

Clinical/Translational RFA's

Early Detection and Risk Assessment in Pancreas Cancer

New Drug Delivery Approaches in Pancreas Cancer

Novel Imaging Technologies in Pancreas Cancer

Novel Therapeutic Agents in Pancreas Cancer

Correlative Studies Awards Program

Preclinical RFA's

Novel Agents for Pancreas Cancer

Clinical and Molecular Markers of Metastic Burden

Basic RFA's

Immune Surveillance and Modulation

Early Stage Target Validation for Pancreas Cancer

Impact of Chromatin Alteration in Pancreas Cancer

New Models of PDAC

American Acne and Rosacea Society Clinical Research Grants

Deadline for submission is December 31, 2013

The American Acne and Rosacea Society (AARS) offers research grants to advance clinical science, while nurturing younger investigators in the field of acne and rosacea. Research projects that are clinical/translational in nature will receive preferential consideration. Up to four (4) clinical research grants will be awarded in 2014 and each grant will not exceed $10,000.

All funds are to be spent within 18 months of receipt of the award. The AARS does not fund projects that are part of the NIH intramural research program or awards to private foundations without an academic affiliation to dermatology.

Eligible Candidates: Dermatology residents and dermatology fellows, and recent graduates (within 5 years) of US dermatology residency are eligible to apply for these research awards. The sponsor (project mentor) of the applicant must be a member of the AARS but may not apply for or be named payee of the grant award.

Proposal: Provide a short discussion of the aims and relevance of the project including sufficient detail for evaluation by the AARS Research Committee. Previously published material may be submitted in support of the application.

Curricula Vitae: Attach a brief biographical sketch of the applicant that should include a recent, relevant bibliography.

Human Subjects: Applications related to research on human subjects must be accompanied by institutional review board approval or submitted prior to the initiation of successful awards.

Animal Studies: Applications that involve research on animals must demonstrate their relevance to clinical dermatology. In addition, they are to be accompanied by a written approval of an appropriate institutional committee or submitted prior to the initiation of successful awards.

Requirements: Within 30 days of completing the approved project, the grantee is required to submit a written report summarizing their research experience and findings. The grantee must also present the work at the AARS annual meeting to be held within two years of funding. If an approved project cannot be completed as originally proposed or in the time limits mandated, the grantee must immediately contact the AARS.

Deadline: The completed application and supporting materials must be received by December 31, 2013. Grant award recipients will be announced at the 2014 AARS Annual Symposium and approved projects will be funded in July 2014.

Request for Proposals: Funding Opportunities for Kennedy’s Disease Research

The Kennedy’s Disease Association (KDA) is planning to fund one or more research grants this fall to further the understanding of the pathological mechanisms of Kennedy’s Disease.

The KDA projects that funding for each grant will be up to $25,000.

Applications from junior investigators and from senior post-doctoral fellows are encouraged.

Your proposals must be received by Friday, June 21, 2013.

Requests for Applications: Biomarkers of Pancreatic Beta Cell Stress and Health

JDRF, the world’s leading non-profit organization with the mission to cure type 1 diabetes (T1D), invites applications from research investigators having interest and expertise to support the discovery and advancement of biomarkers of pancreatic beta cell stress and health correlating with early beta-cell loss.

The purpose of this call for Letters of Intent is to invite proposals to support and advance the discovery, development, and/or validation of biomarkers of pancreatic beta cell stress and dysfunction. Studies based on use or validation with human beta cells/islets and clinical samples or tissues will be of special interest.

MECHANISM

Applications in response to this announcement can be submitted under one of the following funding mechanisms:
Pilot & Feasibility Grants (P&Fs): up to $110,000 (including 10% indirect costs) for one year only.

Strategic Research Agreements (SRAs): Up to $250,000 USD per year including 10% indirect costs
for up to 3 years may be requested. The level of funding will vary depending on the scope and overall objectives of the proposal. Under the terms of the grant award, written quarterly (~2-3 pages) reports will be required from the funded investigator as a basis for continued support.

LETTER OF INTENT

Prospective applicants should submit a letter of intent on -line via the proposalCENTRAL website (https://proposalcentral.altum.com/default.asp).

The LOI template provided on the proposalCENTRAL Web site must be used to complete the application. Applicants will be notified approximately eight weeks after the LOI deadline date if they have been approved to submit a full application.

Letter of Intent Deadline: June 17, 2013.

International Essential Tremor Foundation Grant Program

The IETF grant program provides funds to members of the scientific community who submit proposals that address the nosology, etiology, pathogenesis, treatment or other topics relevant to essential tremor (ET).

The aim of program is to stimulate inquiry into this poorly understood clinical disorder and to provide support to projects that are innovative and give promise of receiving more substantial support from NIH, K Award, R01 and/or other sources if sufficient preliminary information can be obtained from projects supported by the IETF. Preference will be given to individuals who do not currently have any R01 support from NIH.

The IETF would very much like to encourage anyone interested to submit a proposal.

Proposals can be submitted between November 1 and February 28 each year. Questions regarding research funding or grant submission should be directed to Catherine Rice, Executive Director, at 913.341.3880 or email at crice@essentialtremor.org

James Ewing Foundation of the Society of Surgical Oncology and Susan G. Komen for the Cure 2013 Fall Clinical Investigator Award in Breast Cancer Research

Application deadline: Monday, July 8, 2013

Purpose: To promote patient-oriented research conducted by surgical oncologists in clinical and translational science.

Eligibility

Applicants must be surgical oncologists within 10 years of completion of training

Be full SSO members for at least 6 months prior to application submission to be eligible for the award

Applicants must commit to at least 25% effort for this award

Terms of the Award

The award will be funded for two years at $100,000 ($50,000 per year) beginning October 1, 2013.  The Award concludes September 30, 2015.

The award is given to the sponsoring institution and may be used for partial support of applicant’s salary, research fellows or staff support, tuition, travel(no more than $2,000 per year) and/or supplies. No additional funds are available for paying indirect costs.

A brief year-one progress report with a financial update will be required by September 30, 2014. The JEF reserves the right to withhold the second year of support in the event of unsatisfactory progress.

A final report (not to exceed 4 pages) will be required before September 30, 2015. This should include a summary of the project, abstracts and publications acknowledged as supported by this award, and a financial report. Any unexpended funds from the scholarship are to be reimbursed back to JEF.

A brief (up to 10 minutes) presentation of results will be required at the March 2-5, 2016, SSO Annual Cancer Symposium in Boston, MA. 

The James Ewing Foundation of the Society of Surgical Oncology requests a proposal in which the applicant plays a central role in the conduct of a specific clinical research project. This might include for example a leadership role in a clinical trial, in a prospective cancer outcomes study, or a translational research project related to a prospective clinical trial. The clinical research focus must be hypothesis-driven and must have a direct patient-oriented focus.

Clinical trials may be investigator-initiated, industry-driven or organized by a cooperative group. While the applicant need not be the principal investigator of the trial, nor the lead institutional investigator, the extent to which the applicant is involved in study design and conduct must be clearly articulated. Ideal applicants will be early to mid-career investigators with a track record of peer-reviewed research funding who are seeking additional extramural support to further clinical cancer research. Of note, this award is not intended to serve as a career development award for new investigators seeking to initiate their research careers. The track record of the applicant, scientific merit of the application, novelty and clinical impact of the anticipated results, and resources available to ensure completion of the study will comprise the review criteria.

Questions?

Contact the James Ewing Foundation of the Society of Surgical Oncology, Email:  jef@surgonc.org, or phone 847-427-1400, ext. 111, M-F, 8:30 a.m. - 4:30 p.m. (CT).Address:9525 W. Bryn Mawr Ave., Suite 870 Rosemont, Illinois  60018.  Web: www.surgonc.org

Request for Application: Cutaneous Lymphoma Foundation’s CLARIONS Research Awards Program

The signature funding initiative of the Research Awards Program (RAP), is the CLARIONS Grant Program, which stands for Curing Cutaneous Lymphoma by Advancing Research, Innovation and Offering New Solutions.  This research grant program supports investigators interested in conducting innovative cutaneous lymphoma research.   These grants will help uncover causes and improve the treatment and quality of life for patients. Discovering new avenues for better therapies and, one day, a cure for cutaneous lymphoma are key goals of this program.

Research Funding Priorities

Eligibility and Requirements

Investigators at all levels, from clinical and post-doctoral fellows to established investigators, are eligible to receive
awards. Medical students and graduate students are not eligible. Non-U.S. investigators are eligible and the research funded by the RAP can be conducted at non-U.S. institutions. Investigators must be members of an established and recognized academic institution. All research projects involving human subjects must receive IRB approval.

Award Amounts

Each year the CLF will provide two $25,000 awards, renewable for 1 year contingent upon approval by the CLF
Board of Directors based upon the CLF Scientific Review Board’s review and recommendation.

A small indirect cost amount between $1,000-$2,000 is allowable.

The CLF’s RAP seeks to fund innovative research in all areas of cutaneous lymphomas with particular interest in:

-- Etiology and risk factors of cutaneous lymphomas.

-- Measures of disease impact on individuals and populations affected by cutaneous lymphomas.

-- Translating discoveries into diagnostic and therapeutic advances in cutaneous lymphomas.

-- Optimizing therapies for cutaneous lymphomas.

-- Improving quality of life for individuals with cutaneous lymphomas

2013 Calendar of Award Events

January 31 -  Public announcement of Request for Application (RFA)

July 31 -  Application deadline

August - October - Scientific Review Board review

November - Recipients notified of award

December - Grant awards announced at ASH meeting

January, 2014 - Disbursement of Award and beginning of new award cycle

Cutaneous Lymphoma Foundation
PO Box 374
Birmingham, MI 48012-0374

Telephone: 248-644-9014

Fax: 248-644-9014

Call for Research Grant Applications: Cicatricial Alopecia Research Foundation

The Cicatricial Alopecia Research Foundation (CARF) seeks original, focused, and innovative research grant applications dealing with primary cicatricial alopecia (PCA). Applications will be accepted from laboratories around the world. The proposed project must serve to further CARF's research goals, namely, to understand the pathogenesis of PCA, an understanding that will lead to effective prevention and therapy. CARF will give priority to research proposals based on the following topics.

Role of lipids and lipid metabolism in normal hair follicle stem cell biology and cycling

Role of PPARs and other lipid regulators in the pathogenesis of PCA

Role of peroxisomes in hair follicle biology

Role of neuroinflammation in PCA

Role of environmental triggers in the pathogenesis of PCA

Function of sebaceous glands in normal hair follicle biology.

Mechanism of hair shaft egress from the terminal hair follicle

Hair follicle regeneration in a site of tissue repair

GUIDELINES: All applications for grant requests should clearly state research goals, rationale, brief background, and brief experimental protocol. The planned study may not exceed two years in duration. Included in the submission should be a discussion of anticipated results and their potential significance to understanding PCA. Typical awards are $5,000 to $20,000.

A final progress report must be submitted at the end of the funding period. A progress report must be submitted at the end of the first year to obtain a second year no-cost extension. CARF must be acknowledged on all presentations and publications resulting from CARF funded grants.

Applications are reviewed and funded on an annual basis.

Annual application deadline: March 15. Funding decisions made by June 15.

Call for Cancer Projects: Repurposing of Drugs - Breakthrough in Cancer Treatment

Funding Cancer Projects

Reliable Cancer Therapies (RCT) announces € 300 000 for projects repurposing existing drugs for cancer treatment.  The drugs must have been developed and approved for other indication(s). Relevant clinical trial endpoints (cancer survival & tumor response) should be the primary research assessments.

RCT also promotes collaborative research projects between researchers at different universities and/or organisations.

About the Call for Applications

• Medical Degree required for Principal Investigator (PI) or co-PI

• 1 application per PI

• Resubmission is allowed (please indicate the reason for previous decline)

• Set up of proposal:

◦ Application form: maximum 2 pages

◦ in appendix 1: biography & references of the PI and co-PI

◦ in appendix 2: overview of the budget (including salaries, supplies, equipment, patient care costs, and other expenses).

• If your cancer project is selected in the first round, detailled information will be requested for consideration of the final award selections.

• Approved proposals will be supported with a maximum of  € 300 000 for 3 years.

Reliable Cancer Therapies (RCT) is a non-profit organization based in Switzerland that provides research-based information on cancer therapies and selectively funds the development of promising therapies.

RCT investigates information on cancer therapies for evidence to then inform the public about evidence-based cancer treatment choices. We help cancer patients and caregivers to structure and absorb the complex nature of cancer information for their decision-making on registered complementary or alternative therapies.

RCT is continuously looking for cancer therapies that have never been thoroughly examined and consider financing cancer treatments that can be deemed promising based on measurable results.

Application Deadline

Application deadline is June 28, 2013 at 8am GMT. Incomplete or late applications will not be considered.

Please submit applications to Ann-Christine Moenaert (info@reliablecancertherapies.com)

RCT will review the applications internally with the support from our appropriate external experts by August 14, 2013. If the project is selected in the first round, more detailled information will be requested by September 13, 2013.  Final decisions will be made on October 4, 2013.

Contacts at RCT

Please direct any technical questions to Ann-Christine Moenaert (info@reliablecancertherapies.com)

Please contact Gauthier Bouche, MD (info@reliablecancertherapies.com) for any clinical or scientific questions.